|Systematic (IUPAC) name|
Vilanterol (USAN) is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Vilanterol is available on combinations, for example with fluticasone Furoate (Breo in the US; Relvar Ellipta in the UK) or with umeclidinium (Anoro in Europe).
- "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Retrieved 10 May 2013.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.